Incyte (INCY) Announces Multiple Presentations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/4/2026
- S&P 500, Dow hit record highs on strong AI-linked earnings, Mideast deal hopes
- Caterpillar stock jumps on strong earnings and revenue beat
- Optical component stocks rally on proposed U.S. ban on Chinese tech
- BofA says this memory stock could double. Here are 5 reasons why
- Merck shares rise on big Q2 earnings beat, adjusted FY outlook
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Palantir posts 93% revenue growth in Q2 2026, raises full-year outlook
- Grainger CFO resigns, interim replacement named
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Walmart dips after Oppenheimer downgrades shares on difficult short-term setup
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
TD Cowen Reiterates Buy Rating on Incyte (INCY)
June 4, 2025 6:29 AM EDTTD Cowen analyst Marc Frahm reiterated a Buy rating and $86.00 price target on Incyte (NASDAQ: INCY).
The analyst comments "EHA Abstract Shows Promising Efficacy For mCALR In ET We are encouraged by initial data in ET which show '989 driving rapid and robust improvements in platelet counts which met the threshold for hematologic response in the majority of cases. Notably, these outcomes are consistent with several blog posts in online forums which had described deep... More
JPMorgan Reiterates Neutral Rating on Incyte (INCY)
June 3, 2025 3:53 PM EDTJPMorgan analyst Jessica Fye reiterated a Neutral rating and $68.00 price target on Incyte (NASDAQ: INCY).
The analyst comments "Earlier today, closely watched mCALR data (INCA33989) were shared from the first-in-human phase I trial in a late-breaker abstract for EHA (link here). This includes dose-escalation data only in patients with essential thrombocythemia (ET) who were resistant/intolerant to prior therapy and no data were shared in MF. Even though mgmt previously mentioned ET and MF updates might come separately, we... More
Citi Reiterates Buy Rating on Incyte (INCY)
June 3, 2025 1:01 PM EDTCiti analyst David Lebowitz reiterated a Buy rating and $88.00 price target on Incyte (NASDAQ: INCY).
The analyst comments "Incyte announced today that proof-of-concept data for its mCALR inhibitor INCA33989 (abstract HERE) in treating essential thrombocythemia (ET) was accepted as a late-breaking... More
